Strategies to implement CAR-T in DLBCL

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses strategies to implement chimeric antigen receptor T-cell (CAR-T) therapies in diffuse large B-cell lymphoma (DLBCL). Chemoimmunotherapy has good outcomes, but many patients will have relapsed or refractory disease and the standard of care in these situations shows poor results in the long term. The use of CD19 CAR-T constructs improves the outcome and the prognosis in this group of patients, with consolidated data in efficacy and toxicity that allow this therapy to be moved forward to earlier lines of treatment. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.